MedTrace Logo

A Registry-study of ELZONRIS in Participants With BPDCN

NCT07785154 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-08-25

No results posted yet for this study

Summary

The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions

DRUG

Tagraxofusp

No study medication will be provided by the sponsor during this study.

Sponsors & Collaborators

  • Stemline Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Stemline Therapeutics, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-26
Primary Completion
2028-09-30
Completion
2030-06-30

Countries

  • Austria
  • Germany
  • Italy
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07785154 on ClinicalTrials.gov